secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001999371-25-006011
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Pharmaceuticals appoints Joseph Hand as General Counsel and EVP of Operations
--------------------------------------------------------------------------------

- Joseph Hand appointed General Counsel and EVP of Operations, effective May 14, 2025.
- Hand brings over 20 years biopharma experience; served on Celgene's Executive Committee for nearly a decade.
- Played key roles in Celgene's $74B acquisition by BMS and $13.4B divestiture of Otezla to Amgen.
- Appointment comes as Tonix prepares for potential FDA approval of TNX-102 SL for fibromyalgia by August 15, 2025.
- Hand previously served as Chief Administrative Officer at Phathom Pharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125006011/0001999371-25-006011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125006011/tnxp-8k_051425.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-006011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer